Arcuate nucleus: difference between revisions
Diff·revision 20 → 21·11:54, 27 Sep 2025
Difference between revision 20 and revision 21 of Arcuate nucleus. 2 lines changed; the page grew by 234 bytes.
| Revision 20 — 00:08, 4 Sep 2025 TB500_Tarquin (talk) space between number and unit per PP:MOS 5,017 bytes ±0 | Revision 21 — 11:54, 27 Sep 2025 DPP4_Dagmar (talk) expand §Relevance to incretin pharmacology 5,251 bytes +234 | ||
|---|---|---|---|
| 32 | The clinically interesting question is whether sustained agonism produces adaptation in these circuits. Weight regain after discontinuation is rapid and largely complete, which is consistent with the circuits returning to their prior set point rather than being reset by the period of treatment; see [[Weight regain after discontinuation]]. | 32 | The clinically interesting question is whether sustained agonism produces adaptation in these circuits. Weight regain after discontinuation is rapid and largely complete, which is consistent with the circuits returning to their prior set point rather than being reset by the period of treatment; see [[Weight regain after discontinuation]]. |
| 33 | 33 | ||
| + | 34 | Melanocortin-pathway agonists and incretin agonists therefore act on the same axis at different points, and combining them has been proposed but not established as beneficial. Nothing in this article is medical advice.{{r|cone2005}} | |
| + | 35 | ||
| 34 | == References == | 36 | == References == |
| 35 | {{reflist}} | 37 | {{reflist}} |